High-throughput RNA-sequencing reveals novel targets of tofacitinib in the treatment of rheumatoid arthritis
Authors' conclusion
The new discovered circRNA/lncRNA-miRNA-mRNA network in RA patients relevant to tofacitinib therapy will provide new enlightenment for the role of tofacitinib in the treatment of RA and shed light on a new direction for further exploring the deep-seated mechanism of this drug.
Study context
- Population
- Patients with active rheumatoid arthritis (RA)
- Participants
- 14 patients
- Comparison
- Peripheral blood mononuclear cells (PBMCs) before vs after tofacitinib treatment
- Outcome
- Alterations of mRNAs, lncRNAs, circRNAs and miRNAs in PBMCs before and after tofacitinib treatment
Methodological detailsbefore-and-after tofacitinib treatment, whole transcriptome sequencing, qRT-PCR validation
- Before-and-after tofacitinib treatment
- Whole transcriptome sequencing
- qRT-PCR validation
Main finding
As reported in the abstract
Differentially expressed RNAs after vs before tofacitinib
DEmRNAs
69
DElncRNAs
1743
DEcircRNAs
41
DEmiRNAs
4
Original publication
High-throughput RNA-sequencing reveals novel targets of tofacitinib in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. Published 29 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →